We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

STereotactic RadioAblation by Multimodal Imaging for VT (STRA-MI-VT) (STRA-MI-VT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04066517
Recruitment Status : Unknown
Verified February 2021 by Corrado Carbucicchio, Centro Cardiologico Monzino.
Recruitment status was:  Recruiting
First Posted : August 26, 2019
Last Update Posted : February 9, 2021
Istituto Europeo di Oncologia
Information provided by (Responsible Party):
Corrado Carbucicchio, Centro Cardiologico Monzino

Brief Summary:
Study of multimodal-imaging guided stereotactic body radiotherapy (SBRT) for ventricular tachycardia (VT) ablation.

Condition or disease Intervention/treatment Phase
Refractory Ventricular Tachycardia Procedure: SBRT Not Applicable

Detailed Description:

STRA-MI-VT study is a spontaneous, open-label, not randomized, prospective clinical trial.

The objective of the study is to evaluate the safety and efficacy of SBRT in strictly selected patients with refractory VT.

Multimodal cardiac imaging combined with electroanatomic mapping to provide a specific patient's tailored SBRT treatment plan choosing amang different linear accelerators.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Masking Description: No masking in this study.
Primary Purpose: Treatment
Official Title: STereotactic RadioAblation by Multimodal Imaging for VT (STRA-MI-VT)
Actual Study Start Date : September 13, 2019
Estimated Primary Completion Date : September 13, 2022
Estimated Study Completion Date : January 13, 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Open Label
Non-randomized, open label clinical trial that intends to treat with SBRT 15 patients with refractory VT.
Procedure: SBRT
Multimodal-imaging guided SBRT for VT ablation.

Primary Outcome Measures :
  1. SBRT safety during 12 month follow-up [ Time Frame: 12 months ]
    Serious adverse events will be defined using CTCAE v4.0 criteria.

  2. SBRT efficacy based on reduction of VT episodes during 12 month follow-up [ Time Frame: 12 months ]
    There will be 6 week blanking period after therapy to allow for ablation effect

Secondary Outcome Measures :
  1. Total mortality [ Time Frame: 12 months ]
  2. Health related quality of life [ Time Frame: 12 months ]
    Health related quality of life for positive or negative changes based on score from SF-36 Questionnaire

  3. Cardiac functional changes [ Time Frame: 12 months ]
    Cardiac functional changes evaluated by echocardiography ejection fraction

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ICD/S-ICD recipients with refractory VT
  • Not eligible for conventional catheter ablation or -in alternative- that have undergone failing conventional catheter ablation attempts, refusing surgery for the treatment of the arrhythmia.
  • LVEF ≥ 20%.
  • Age ≥ 50 years.
  • Signed an IRB approved written informed consent document.

Exclusion Criteria:

  • Previous radiotherapy with cardiac involvement.
  • Pregnancy or breastfeeding.
  • Active myocardial ischemia.
  • Acute revascularation in the past 120 days.
  • Acute hemodynamic instability (cardiogenic shock/NYHA IV).
  • Serious disease with presumed life expectancy less than 12 months.
  • Any condition that is deemed a contraindication in the judgment of the investigators.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04066517

Layout table for location contacts
Contact: Corrado Carbucicchio, MD +39 02 58001626 corrado.carbucicchio@ccfm.it
Contact: Valentina Catto, PhD +39 02 58002856 valentina.catto@ccfm.it

Layout table for location information
Centro Cardiologico Monzino, IRCCS Recruiting
Milano, MI, Italy, 20138
Contact: Corrado Carbucicchio, MD    +39 02 58001626    corrado.carbucicchio@ccfm.it   
Contact: Valentina Catto, PhD    +39 02 58002856    valentina.catto@ccfm.it   
Principal Investigator: Corrado Carbucicchio, MD         
Sub-Investigator: Daniele Andreini, MD, PhD         
Istituto Europeo di Oncologia, IRCCS Active, not recruiting
Milano, MI, Italy, 20141
Sponsors and Collaborators
Centro Cardiologico Monzino
Istituto Europeo di Oncologia
Layout table for additonal information
Responsible Party: Corrado Carbucicchio, Head of Ventricular Intensive Care Unit, Centro Cardiologico Monzino
ClinicalTrials.gov Identifier: NCT04066517    
Other Study ID Numbers: R 918/19 - CCM968
First Posted: August 26, 2019    Key Record Dates
Last Update Posted: February 9, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Tachycardia, Ventricular
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Cardiac Conduction System Disease
Pathologic Processes